NEW YORK — Antibody drug discovery and development firm Infinimmune said on Tuesday that it has partnered with Grid Therapeutics to identify new drug candidates for non-small cell lung cancer.
Under the terms of the deal, the companies will use Infinimmune's Anthrobody drug-discovery platform and its Complete Human immunosequencing technology to study the antibody repertoire of non-small cell lung cancer patients and control patients selected on the basis of their clinical status and response to standard-of-care chemotherapies and immunotherapies.
The companies aim to use this data to understand differences and similarities between the antibody responses of individuals with lung cancer progression, according to San Francisco-based Infinimmune.
"We aim to take full advantage of Infinimmune's truly human antibody data, to efficiently identify better and safer therapeutics," Grid CEO Edward Patz said in a statement.
Grid, based in Durham, North Carolina, currently has two antibody-based drugs in clinical development, both for non-small cell lung cancer.